SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Buonaguro FM)
 

Sökning: WFRF:(Buonaguro FM) > (2007-2009) > DNA-VLP prime-boost...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003666naa a2200409 4500
001oai:DiVA.org:liu-38564
003SwePub
008091010s2007 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:115758827
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-385642 URI
0247 a https://doi.org/10.1016/j.vaccine.2007.05.0522 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1157588272 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Buonaguro, Lu Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy4 aut
2451 0a DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
264 1b Elsevier BV,c 2007
338 a electronic2 rdacarrier
520 a The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime-boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2-V5 region in the heterologous prime-boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA-VLP heterologous prime-boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3. © 2007 Elsevier Ltd. All rights reserved.
653 a MEDICINE
653 a MEDICIN
7001 a Devito, Cu Linköpings universitet,Molekylär virologi,Hälsouniversitetet4 aut
7001 a Tornesello, MLu Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy4 aut
7001 a Schröder, Uu Eurocine Vaccines AB, Sweden4 aut
7001 a Wahren, Bu Karolinska Institutet4 aut
7001 a Hinkula, Jorma,d 1958-u Linköpings universitet,Hälsouniversitetet,Molekylär virologi4 aut0 (Swepub:liu)jorhi40
7001 a Buonaguro, FMu Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy4 aut
7102 a Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italyb Molekylär virologi4 org
7730 t Vaccined : Elsevier BVg 25:32, s. 5968-5977q 25:32<5968-5977x 0264-410Xx 1873-2518
8564 u https://liu.diva-portal.org/smash/get/diva2:259413/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint
8564 u http://liu.diva-portal.org/smash/get/diva2:259413/FULLTEXT01
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-38564
8564 8u https://doi.org/10.1016/j.vaccine.2007.05.052
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:115758827

Hitta via bibliotek

  • Vaccine (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy